Multiple Biopharma Leaders Participate in Morgan Stanley Global Healthcare Conference Sept 8-9

Several leading biopharmaceutical companies, including Royalty Pharma, Madrigal Pharmaceuticals, and Merck & Co., are set to participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in early September 2025. Royalty Pharma will discuss its extensive portfolio of royalties on major therapies and its role in funding biopharmaceutical innovation. Madrigal Pharmaceuticals will highlight its FDA- and European Commission-approved drug Rezdiffra for metabolic dysfunction-associated steatohepatitis (MASH), alongside ongoing clinical trials. Merck's top executives, including CEO Robert M. Davis and Dr. Dean Y. Li, will engage in a fireside chat emphasizing the company's leadership in healthcare innovation, commitment to transparency, and ongoing research initiatives. The Merck presentations will be webcast live to investors, analysts, and the public, underscoring the company's efforts to maintain investor confidence amid potential risks related to regulatory and developmental challenges. These participations collectively demonstrate the industry's focus on advancing treatments and fostering innovation through collaboration and direct engagement with stakeholders.